Latest news with #PE
Mint
18 hours ago
- Business
- Mint
Yes Bank share price falls over 7% amid block deal buzz, ahead of board meet to consider fundraising
Yes Bank share price plunged over 7% in early trade on Tuesday, breaking its three-day gaining streak. Yes Bank shares fell as much as 7.39% to ₹ 21.55 apiece on the BSE. The fall in Yes Bank share price comes amid reports of block deal and ahead of its board meeting to consider fundraising. According to a report by CNBC-TV18, around 3% equity shares of Yes Bank changed hands in multiple blocks in Tuesday's trade. The report added that a PE investor was likely the seller of Yes Bank shares in the block deals today. Meanwhile, the board of directors of the private lender will meet today to consider proposals to raise capital through the issuance of equity shares or debt securities, via private placement or preferential allotment, subject to requisite approvals. '...this is to inform that the meeting of the Board of Directors of YES Bank Limited is scheduled to be held on Tuesday, June 03, 2025, inter alia, to consider raising of funds by way of issuance of equity shares, debt securities and/or any other eligible securities (convertible/non-convertible) through permissible modes, including but not limited to a private placement, preferential issue or any other method or combination of methods, subject to such approvals as may be required,' Yes Bank announced in a regulatory filing on May 28. Yes Bank also said that its trading window for designated persons and insiders will remain closed from May 29 until two days after the outcome of the board meeting is disclosed to the stock exchanges. Yes Bank share price has recently witnessed a strong rally, gaining 23% in one month and rising 11% on a year-to-date (YTD) basis. Yes Bank shares have gained 4% over the last six months, but the banking stock has dropped 7.5% in one year. However, Yes Bank share price has delivered 32% returns in two years. At 9:20 AM, Yes Bank share price was trading 6.79% lower at ₹ 21.69 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
3 days ago
- Business
- Time of India
Is Nike failing Caitlin Clark? Former insider call out brand for mishandling WNBA star
Caitlin Clark. Image via: Jesse D. Garrabrant/NBAE via Getty Images Caitlin Clark, the Indiana Fever star and arguably the most influential figure in women's basketball today, is at the center of growing criticism aimed at Nike. In April 2024, The sportswear giant signed Clark to a landmark eight-year, $28 million endorsement deal shortly after she was selected as the No. 1 overall pick in the 2024 WNBA Draft. But more than a year later, many, including former insiders, believe Nike has fallen far short of fully leveraging her unprecedented star power. Despite her fame, Clark has yet to receive a signature shoe. Over a year into the partnership, she has only received Player Exclusive (PE) sneakers from Nike's Kobe series. She has not been given a signature sneaker line or branded merchandise, marketing tools that are typically awarded to less accomplished male athletes. While she has appeared on national billboards and in a Super Bowl commercial, fans and insiders alike are questioning why Nike is holding back. In June 2024, when asked when her first signature shoe might arrive, Clark told reporters: 'I don't make those decisions so you'll have to wait and see.' At the time, she had not yet earned WNBA Rookie of the Year honors, which she would go on to receive in October 2024. Ex-marketing director speaks out The loudest critique came this week from Jordan Rogers, a former Brand Marketing Director for Nike Basketball, who spent over a decade at the company. In a TikTok video, Rogers accused Nike of mishandling Clark's immense marketability. He questioned the disparity between Nike's treatment of male and female athletes and how Clark, arguably the most culturally significant player since Jordan, hasn't received the same investment. "You have the single biggest needle mover in all of American sports since Michael Jordan , and you have somehow convinced yourself that you need to slow-play this?" Rogers said. He continued, "This seems like you have convinced yourself that this needs to be an either/or conversation. And we never have an either/or conversation in the men's sports , you have like 10 signature athletes [in the NBA], half of them don't deserve a signature shoe." Rogers further speculated that political backlash surrounding Clark may be making Nike hesitant to go all-in. "I am so confused as to why you wouldn't be doing bigger campaigns with [Clark]... One of the best explanations I can come up with is that you are wringing your hands and afraid to enter into this politically divisive conversation that has been co-opted by the media and pundits," he said. He ended his message to Nike with a plea: "You have the unicorn, the chosen one, the one who everyone wants to hear from, and you are just sitting around... Please, for the love of God, figure something out." Comparisons and fan frustration Clark's influence is undeniable. During her college career at Iowa, she played in two of the most-watched women's college basketball games in history. Her 2024 Elite Eight game against LSU drew 16 million viewers. Her presence at the WNBA Draft that year attracted a record 2.4 million viewers. In the WNBA, she has already claimed Rookie of the Year honors and is among the frontrunners for MVP this season. Yet, despite being one of the league's biggest stars, Clark lacks something her rookie classmate Angel Reese has secured: a signature shoe. Reese, who plays for the Chicago Sky, is set to release her own signature sneaker with Reebok on June 4. Fans have expressed confusion and disappointment, asking why Nike hasn't moved quicker to give Clark her own line , especially given her unmatched visibility and performance. Others are doing it better R ogers praised other brands , including Gatorade, State Farm, and Wilson , for doing a better job of embracing Clark's commercial appeal. 'Gatorade, State Farm and Wilson have all done a much better job in maximizing the value of the WNBA's 'unicorn' superstar,' he added. Fans have become increasingly vocal online, questioning Nike's apparent hesitation to give Clark her own brand line. Rogers' criticism only added to a growing sense of frustration. "I am so confused as to how you would be so invested in the WNBA for several years and you've been doing great work trying to elevate and uplift that league and many of the athletes," he said. As Nike faces mounting public pressure, the question remains: will they shift gears and give Clark the platform her popularity clearly demands? For now, all eyes, and expectations, remain on the brand to step up.
Yahoo
5 days ago
- Business
- Yahoo
Premix opens new manufacturing facility in North Carolina
Premix Group, an electrically conductive plastics manufacturer, has inaugurated its new manufacturing facility in Apple Creek, North Carolina, US. The development of the facility was backed by a $79m investment from the US Department of Health and Human Services. It is expected to strengthen the domestic supply chain for crucial diagnostics and other high-impact applications. The facility will utilise US-sourced raw materials to produce advanced polyethylene- (PE) and polypropylene (PP)-based compounds and concentrates. These materials are seen as key for extrusion and injection moulding applications, enabling accurate liquid level detection and providing protection against uncontrolled electrostatic discharges. Such features are essential in diagnostics, chemicals, electronics, industrial packaging, and other high-performance applications. The Apple Creek plant will offer the US market locally manufactured products with reduced lead times, a smaller carbon footprint, and better supply chain security. Premix Group CEO Jaakko Aho said: "These materials enable high-precision liquid level sensing in diagnostic testing, and safer handling, transport, and storage by protecting against uncontrolled electrostatic discharges (ESD) - a critical requirement in electronics, industrial packaging, diagnostics, and other high-performance applications. "Establishing a manufacturing presence in the United States is about more than production - it's about building resilient supply chains and trusted partnerships." This strategic move expands Premix's global presence, building upon its foundation as a family-owned business established in Finland in 1983. Premix has production facilities in both Finland and the US, offering material solutions designed to improve safety and operational efficiency. "Premix opens new manufacturing facility in North Carolina" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Medscape
7 days ago
- Health
- Medscape
You Can Manage Pulmonary Embolism in Primary Care
About 900,000 people are affected by pulmonary embolism (PE) each year in the United States, according to the American Lung Association and about 100,000 people die each year as a result of the disorder. However, some patients diagnosed with PE may be at low risk for adverse outcomes, and some experts suggest primary care physicians (PCPs) can effectively manage these low-risk patients. According to some research, it's both possible and feasible. Another potential benefit: Research also suggests that outpatient treatment for low-risk patients could reduce the burden on the healthcare system while reducing costs. Detailed Assessment to Determine 'Low Risk' The concept of treating low-risk patients with PE at home is not new. A 2022 study in the Journal of General Internal Medicine described how 652 patients diagnosed with PE in the primary care setting of a large community-based health system fared. The researchers found a very low incidence of 7-day PE related hospitalization and a low rate of 30-day serious adverse events among the adult patients who were not transferred to the emergency department or hospital. Also, in August 2022, a panel reviewed the American Society of Hematology (ASH)'s guidelines on managing deep vein thrombosis (DVT) and PE and suggested that home treatment is a possible option. The ASH Clinical Practice Guidelines on Venous Thromboembolism (VTE) stated, 'The panel also made conditional recommendations expressing a preference for home treatment over hospital-based treatment of uncomplicated cases of DVT and PE. Home treatment is suggested when there is a low risk for complications as well as a preference for direct oral anticoagulants for primary treatment of VTE.' One major component of this option, however, is making sure that a patient is actually at low risk. In fact, the authors of the Journal of General Internal Medicine study also noted that the patients diagnosed with PE in primary care tended to be at low risk, and making that determination is crucial. Typically, physicians who suspect PE begin with a physical examination of the patient. While the physician's clinical gestalt is important, many also use clinical probability scoring systems such as the Wells criteria to assess factors such as a patient's immobility, clinical symptoms of DVT, a previous DVT or PE, and hemoptysis, or the Geneva scoring system. The diagnosis of PE requires imaging studies such as computed tomographic pulmonary angiography, and lab tests, notably the D-dimer test, to confirm the likelihood of a PE. The next step is determining if the patient is at low, intermediate, or high risk. That information is crucial to making a decision about how to proceed, whether it's initiating anticoagulation treatment on an outpatient basis and sending the patient home, or it's directing the patient to go directly to the emergency department. Pulmonologist Gustavo Heresi, MD, Cleveland Clinic, Cleveland, emphasized the importance of risk stratification to determine the likely prognosis for patients once they've been diagnosed with PE. The most commonly used prognostic tool is the Pulmonary Embolism Severity Index (PESI) index, which predicts 30-day mortality in patients with PE, and its simplified version, the sPESI, which uses fewer criteria but produces comparable accuracy results. Physicians can also use the Hestia criteria, Heresi said. Gustavo Heresi, MD If a physician determines that a patient is at low risk, then it can be appropriate for a PCP to manage the patient's condition. 'The initial management can be done in the primary care setting,' said Sai Sunkara, MD, a pulmonologist with UI Health in Chicago. In fact, it's easier now than in the past, given the advances in anticoagulation therapy, such as the use of direct oral anticoagulants. 'Low-risk patients who are stable and minimally at risk, can be treated at home after getting their diagnosis and a treatment plan,' agreed Heresi. But he cautioned that he can't envision the normalization of treating intermediate- or higher-risk patients in a nonemergent setting. 'I don't think that's likely to be conducive to an outpatient treatment management plan,' he said. Even for low-risk patients, there may be some barriers to outpatient management. According to Geoff Chupp, MD, professor of medicine (pulmonary, critical care, and sleep medicine) at the Yale School of Medicine, New Haven, Connecticut, not every primary care office may have the necessary diagnostic equipment, such as CT machines. What PCPs Already Do PCPs already play a key role in caring for patients affected by PE. For example, they may educate patients at elevated risk for DVT because DVT can lead to a PE. Risk factors include cancer, a history of prior thromboembolism, pregnancy, and certain medical conditions, as well as people who have recently undergone surgery or spent time immobilized 'That's generally what we try to do is educate people,' said Lori Solomon, MD, MPH, a family physician and director of the Family Health Center at New York Medical College in Valhalla, New York. 'But sometimes you don't expect people to come in with pulmonary embolisms, so sometimes you just have to be vigilant when people come in and listen to their symptoms and take them seriously.' Lori Solomon, MD, MPH Even if the PCP does not take on the initial treatment of a PE, they still play a key role later. Around the 3-month mark, some patients become less adherent with treatment, said Branden Turner, MD, a family medicine physician with Kaiser Permanente in Los Angeles. 'It's just human nature,' he said. 'The initial fear is gone, but you still need to take your medications.' He sets up telephone appointments at regular intervals to check in with patients. However, some patients may not realize when they can discontinue their anticoagulation therapy, and PCPs can take on that role, too, said Solomon. 'It's easy to start a medication, but sometimes people forget to stop it,' she said. Prioritizing Social Determinants of Health Before a physician contemplates sending a low-risk patient home on anticoagulant therapy, they need to find out some key pieces of information. For example, Wilson Pace, MD, professor emeritus in family medicine, Anschutz Medical Campus of the University of Colorado, Aurora, Colorado, suggested determining: What is the patient's living situation? Do they have someone at home who can help them, or do they live alone? Is it possible to arrange for a home health nurse to check in on the patient at home? Does the patient have a pulse oximeter and blood pressure monitor to use at home? Branden Turner, MD PCPs are already well positioned to have or gather this type of information, said Solomon. 'That is why having a PCP is so important,' she added. 'Treatment plans and follow-up are very dependent on a patient's support system and living conditions.' Turner agreed. 'This is the crux to me of a good primary care physician: Being able to personalize the care to the patient based on the individual to get the best outcome for them,' he said. 'Health equity in practice. As long as the plan works for the patient and is safe, I'm open to navigate how to achieve the goal.'
Scotsman
26-05-2025
- Business
- Scotsman
Circular economy: The Scottish start-up behind ‘simple solution' for recycling plastic
'Plastics are an essential part of our world, but so far, the industry has failed to provide workable solutions at-scale to deal with the impact they have on our environment' – Tom Rose, ReVentas Sign up to our Scotsman Money newsletter, covering all you need to know to help manage your money. Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... A Scottish start-up has secured international investment to scale up its ground-breaking plastic recycling technology. Livingston-based ReVentas is looking to go from pilot plant to commercial operation over the next three years. The funding round has been backed by venture capitalists Orlen VC and Beiersdorf Venture Capital, and economic development agency Scottish Enterprise. Advertisement Hide Ad Advertisement Hide Ad Dealing with plastic at end-of-life remains a challenge for society, with recycling rates of only around 9 per cent globally. This is due to the complex composition of materials, their colour and the contamination they have picked up, resulting in the majority being incinerated. Any plastic that is recycled is often being downcycled into low value applications. Livingston-based ReVentas' pilot plant for plastic recycling. ReVentas' recycling technology aims to solve this problem, tackling two of the most common plastics in use today, polyethylene (PE) and polypropylene (PP), making up more than half of the plastic produced. The firm's unique tech uses a chemical solvent to rapidly dissolve PE and PP, filtering the plastic of all contaminants including colour and odour, and producing a natural 'like-new' plastic which can be sold directly to end customers, replacing virgin plastic. The technology operates at low temperatures and pressures, which is said to cut the cost of production making recycling more economically viable, while achieving an 80 per cent reduction in carbon emissions over new plastic production. Tom Rose, chief executive of ReVentas, said: 'This investment marks a major milestone for ReVentas and in moving the recycling of plastic forward. Plastics are an essential part of our world, but so far, the industry has failed to provide workable solutions at-scale to deal with the impact they have on our environment. Advertisement Hide Ad Advertisement Hide Ad 'ReVentas are providing a simple solution which can change this, ensuring the waste we produce today, can and will be directly used in the products we buy tomorrow.' Derek Shaw, director of entrepreneurship and investment at Scottish Enterprise, said: 'Our investment support is focused on helping Scotland's most innovative and ambitious companies to grow and scale, creating impactful economic change. 'ReVentas is a shining example of this, by working in an area where Scotland has global strengths to develop innovative solutions for one of the biggest global environmental challenges we face right now.' Beiersdorf Venture Capital and Orlen VC will join LG Chem and others as strategic partners of ReVentas to support the scale up of the technology. With the funding secured, the goal is to accelerate the development of the company's first commercial 10,000-tonne-per-annum plant, planned for operation in 2027, with an additional 140,000 tonnes planned to be brought online by 2031. Advertisement Hide Ad Advertisement Hide Ad Marek Garniewski, president of the management board of Orlen VC, said: 'EU regulations mandate that 10 per cent of packaging materials must come from recycled sources by 2030. However, Europe faces significant shortages of high-quality secondary raw materials suitable for reuse in production.
